addressing leukemic transformation in mds: ongoing challenges and future outlooks
Published 1 year ago • 48 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
3:22
performance of the aipss-mds ml model in predicting os & leukemic transformation in cmml
-
0:55
the role of rna modifications in mds and aml
-
1:36
innovations in mds and aml treatment
-
3:21
an insight into the standard of care in hr-mds and future outlooks
-
1:41
the future of aml and mds diagnosis and treatment
-
2:16
current and future treatment approaches for hr-mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:43
novel therapies in the future of mds treatment
-
4:28
understanding myelodysplastic syndromes (mds)
-
4:48
managing and treating mds
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:17
phase ii study of tosedostat in mds
-
1:50
germline predispositions in myelodysplastic syndromes (mds) and acute myeloid leukemia (aml)
-
2:53
a 5-year follow-up of ruxolitinib plus azacitidine in mds/mpn overlap syndromes and cmml
-
1:17
exciting novel treatments being developed for mds
-
11:06
the future treatment of acute leukemias: part i
-
2:38
managing the progression of mds to aml
-
5:06
personalized therapy for mds: advancements and the future
-
5:43
pre- and post-allohsct treatment in mds
-
1:26
effective immunomodulation with pomalidomide during induction tst for aml and mds